Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents.

Authors:
Cohen H; Stefanutti C; The Mighty Medic Satellite Research Group for Pediatric Dyslipidemia.

Journal:
Curr Atheroscler Rep

Publication Year: 2021

DOI:
10.1007/s11883-021-00926-3

PMCID:
PMC8105241

PMID:
33963467

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Atheroscler Rep

Abbreviation: Curr Atheroscler Rep

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams T; Nelson AJ; Nicholls SJ. (2024) - Transparency Score: 3/6
Lipoprotein(a): from Causality to Treatment.
Kronenberg F. (2024) - Transparency Score: 3/6
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma S; Sahebkar A; Banach M. (2024) - Transparency Score: 2/6
Apheresis: What Should a Clinician Know?
Parhofer KG. (2023) - Transparency Score: 3/6
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB and 1 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest The authors declare that they have no conflict of interest."

Evidence found in paper:

"Funding Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025